Ellerson Group’s AbbVie ABBV Stock Holding History

Ellerson Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-700	Closed	-$104K	–	48
2023 Q3	$104K	Buy	+700	New	+$103K	0.1%	64

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ellerson Group's ABBV Position: Q4 2023 in Review

Ellerson Group sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 700 shares — an estimated $104K sold.

Ellerson Group first reported a position in ABBV in Q3 2023 and held it in 1 quarter. The position peaked at $104K in Q3 2023. 3,322 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

Ellerson Group reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
Ellerson Group sold 700 AbbVie shares in Q4 2023, an estimated $104K.
Ellerson Group first reported a position in AbbVie in Q3 2023 and held it in 1 quarter.
Ellerson Group's AbbVie position peaked at $104K in Q3 2023.
3,322 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on Ellerson Group's 13F filing for Q4 2023, filed 6 Feb 2024.